On April 24, 2018 Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA) constructs, reported that the Company’s Chief Executive Officer, David Giljohann, Ph.D., has been recognized by Endpoints News as an outstanding up-and-coming biopharma professional under the age of 40 (Press release, Exicure, APR 24, 2018, View Source;p=RssLanding&cat=news&id=2344263 [SID1234525632]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Giljohann was Exicure’s founding scientist in 2011. He has served as Chief Executive Officer since November 2013 and on the Company’s Board of Directors since March 2014. He completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including Exicure’s Spherical Nucleic Acid (SNA) constructs.

"It is an incredible honor to be recognized in Endpoints News’ under-40s biopharma professionals list," states Dr. Giljohann, 37. "I would like to see a dramatic change in how quickly we can design and develop drugs for patients in need, and this is a driving force for our team at Exicure. With three drugs now in the clinic, we hope that the advancement of our SNA technology can provide great promise for a broad range of chronic conditions and orphan diseases."

Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. He received his Ph.D. in 2009 from Northwestern University.